Retrospective, real-world data analysis showed pts with MM who received BsAbs and developed VTE had significantly shorter OS and higher risk of death.

IRAKLIA, the first phase 3 multiple myeloma study to use an on-body injector, finds the same efficacy and pharmacokinetics in ...

The investigational combo resulted in an ORR of 78.9%, with over half of the subjects achieving a complete response or better ...

A former footballer has told how he was in "complete shock" after being diagnosed with blood cancer - after first believing ...

By the time her cancer was caught, six months after her symptoms began and two days after her 46th birthday, Louise Greenbank ...

Paul Silvester, from Sheffield, was diagnosed with Myeloma in July 2023 after his cancer caused broken vertebrae in his spine ...

The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Patients with relapsed/refractory (R/R) multiple myeloma and lower socioeconomic status reported significantly worse quality of life and a higher burden of symptoms, according to Francesco Sparano, ...

A Sheffield man has become one of the first patients in the world to benefit from a pioneering therapy that could halt the ...

Terminal patients could get years more with their loved ones as the NHS offers Blenrep, which can put some blood cancer patients in remission ...

The NHS in England will be the first health system in the world to roll-out a ‘trojan horse’ targeted therapy for blood cancer patients which could halt the disease’s progression by nearly three times ...